Supplementation with a Salmon Bone Complex (CalGo(®)) Preserves Femoral Neck BMD and Attenuates Lumbar Spine Loss: A 24-Month Randomized, Placebo-Controlled Trial

补充鲑鱼骨复合物(CalGo®)可维持股骨颈骨密度并减缓腰椎骨质流失:一项为期24个月的随机、安慰剂对照试验

阅读:1

Abstract

Background/Objectives: Osteopenia is common in postmenopausal women and predisposes to osteoporosis and fracture, representing a population at risk of bone loss but without indication for pharmacologic therapy. Conventional calcium salts offer modest, often transient gains in bone mineral density (BMD). We evaluated whether CalGo(®), a salmon bone complex containing microcrystalline hydroxyapatite within a collagen-rich matrix, preserves BMD versus placebo in post-menopausal women with osteopenia. Methods: In a 24-month, randomized, double-blind, placebo-controlled trial, 80 women (50-80 years) with dual-energy X-ray absorptiometry (DXA)-confirmed femoral-neck osteopenia were assigned to CalGo(®) (2 g/day) or placebo. The prespecified primary endpoint was 24-month change in femoral-neck BMD (g/cm(2)) analyzed by linear regression (unadjusted and baseline-adjusted). Secondary endpoints included lumbar spine and distal radius BMD, serum P1NP and β-CTX-I, health-related quality of life, and safety. Results: The primary analysis included participants with 24-month DXA (CalGo(®)n = 29; placebo n = 30). Femoral-neck BMD was maintained with CalGo(®) (+0.003 g/cm(2); +0.4%) but declined with placebo (-0.017 g/cm(2); -2.4%), yielding a significant baseline-adjusted between-group difference of +0.019 g/cm(2) (95% confidence interval (CI) 0.001-0.038; p = 0.044). Lumbar-spine loss was attenuated with CalGo(®) (-0.005 g/cm(2); -0.3%) versus placebo (-0.028 g/cm(2); -3.4%); the adjusted difference favored CalGo(®) (+0.026 g/cm(2); p = 0.058). In exploratory responder analysis, ≥1% lumbar-spine gain was more likely with CalGo(®) (32.5% vs. 11.4%; OR 3.61; p = 0.043). No treatment effects were observed at the distal radius, in P1NP or β-CTX-I, or in EQ-5D-3L/EQ-VAS. CalGo(®) was well tolerated with no hepatic or renal safety signals. Conclusions: CalGo(®) maintained femoral-neck bone mineral density and reduced lumbar-spine loss over 24 months in osteopenic women, with good tolerability. These findings support its potential role as a nutritional approach for maintaining bone health.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。